Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kanerva

Showing results (51-60 of 124) with videos related to

Pageof 13
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic ImmunotherapyKristian Taipale, Ilkka Liikanen, Anniina Koski, et al.
Molecular Therapy Oncolytics|April 28, 2016
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesKaroliina Autio, Anna Knuuttila, Anja Kipar, et al.
Molecular Therapy Oncolytics|December 21, 2018
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic AdenovirusRiikka Havunen, João M Santos, Suvi Sorsa, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 13, 2026
Post-operative venous thromboembolism in advanced epithelial ovarian cancer: risk factors, tumor gene expression, and survivalMatilda Salko, Lasse Myllylahti, Sara Palomino-Echeverria, et al.
Frontiers in Immunology|June 4, 2021
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor ControlDafne C A Quixabeira, Sadia Zafar, Joao M Santos, et al.
International Journal of Radiation Oncology, Biology, Physics|September 14, 2010
Adenoviral E4orf3 and E4orf6 proteins, but not E1B55K, increase killing of cancer cells by radiotherapy in vivoIlkka Liikanen, João D Dias, Petri Nokisalmi, et al.
International Journal of Cancer|July 1, 2014
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcomaMikko Siurala, Simona Bramante, Lotta Vassilev, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Oncolytic adenovirus decreases the proportion of TIM-3<sup>+</sup> subset of tumor-infiltrating CD8<sup>+</sup> T cells with correlation to improved survival in patients with cancerIlkka Liikanen, Saru Basnet, Dafne C A Quixabeira, et al.
Diseases (Basel, Switzerland)|August 23, 2022
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian CancersCamilla Heiniö, James Clubb, Tatiana Kudling, et al.
International Journal of Cancer|August 12, 2011
Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancerLotta Kangasniemi, Suvi Parviainen, Tommi Pisto, et al.
Pageof 13

Showing results (51-60 of 124) with videos related to

Sort By:
Pageof 13
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 5, 2016
Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic ImmunotherapyKristian Taipale, Ilkka Liikanen, Anniina Koski, et al.
Molecular Therapy Oncolytics|April 28, 2016
Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesKaroliina Autio, Anna Knuuttila, Anja Kipar, et al.
Molecular Therapy Oncolytics|December 21, 2018
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic AdenovirusRiikka Havunen, João M Santos, Suvi Sorsa, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 13, 2026
Post-operative venous thromboembolism in advanced epithelial ovarian cancer: risk factors, tumor gene expression, and survivalMatilda Salko, Lasse Myllylahti, Sara Palomino-Echeverria, et al.
Frontiers in Immunology|June 4, 2021
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor ControlDafne C A Quixabeira, Sadia Zafar, Joao M Santos, et al.
International Journal of Radiation Oncology, Biology, Physics|September 14, 2010
Adenoviral E4orf3 and E4orf6 proteins, but not E1B55K, increase killing of cancer cells by radiotherapy in vivoIlkka Liikanen, João D Dias, Petri Nokisalmi, et al.
International Journal of Cancer|July 1, 2014
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcomaMikko Siurala, Simona Bramante, Lotta Vassilev, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
Oncolytic adenovirus decreases the proportion of TIM-3<sup>+</sup> subset of tumor-infiltrating CD8<sup>+</sup> T cells with correlation to improved survival in patients with cancerIlkka Liikanen, Saru Basnet, Dafne C A Quixabeira, et al.
Diseases (Basel, Switzerland)|August 23, 2022
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian CancersCamilla Heiniö, James Clubb, Tatiana Kudling, et al.
International Journal of Cancer|August 12, 2011
Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancerLotta Kangasniemi, Suvi Parviainen, Tommi Pisto, et al.
Pageof 13